TGFBR2 and benign prostatic hyperplasia: We found that systemic blockade of TGF‐β activity or conditional deletion of the TGF‐β receptor II (Tgfbr2) in nestin+ cell lineage attenuated stromal hyperplasia with potential as an effective therapy for human BPH.